New Drugs for Atherosclerosis

Caroline S. Bruikman, Robert M. Stoekenbroek, G. Kees Hovingh, John P. Kastelein

Research output: Contribution to journalReview articleAcademicpeer-review

16 Citations (Scopus)


Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CVD), is caused by the multifactorial interaction of various conditions, and dyslipidemia is widely acknowledged as 1 of the crucial risk factors in this process. Statin drugs have been shown to decrease low-density lipoprotein cholesterol and CVD morbidity as well as mortality and are therefore pivotal in CVD prevention. Despite the use of statin drugs, CVD remains a leading cause of mortality worldwide, which suggests that additional lipid-lowering therapies are warranted. Several novel therapeutic agents, which are described in this review, are now well on their way in their respective development paths and might revolutionize anti-atherosclerotic drug therapy
Original languageEnglish
Pages (from-to)350-357
JournalCanadian journal of cardiology
Issue number3
Early online date2016
Publication statusPublished - 2017

Cite this